This trial is active, not recruiting.

Condition disruptive behavior disorder
Treatments coping power, individualized treatment
Sponsor Centre for Addiction and Mental Health
Collaborator Ontario Mental Health Foundation
Start date July 2010
End date December 2016
Trial size 112 participants
Trial identifier NCT02488499, 091/2010-03


This study investigates the effectiveness of a clinic-adapted version of the Coping Power program compared to individualized child and family treatment for children with disruptive behaviour and their parents.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
(Active Comparator)
Individualized Treatment: 15 sessions of individualized treatment (i.e., parent-child) that target areas of presenting concern identified during assessment. These may include social problem-solving, emotion regulation, parent-child difficulties.
individualized treatment
15 sessions of individualized child and parent treatment
Coping Power: 15 sessions of concurrent parent and child group treatment. The child group focuses on developing problem-solving and emotion regulation skills. The parent group focuses on developing parenting skills and problem-solving strategies to manage and reduce their children's disruptive behaviour.
coping power
15 sessions of concurrent parent and child group treatment

Primary Outcomes

Conduct Problems scale score measured by the Strengths and Difficulties Questionnaire
time frame: Change from Baseline Conduct Problems at 15-weeks and at 6 months

Eligibility Criteria

Male or female participants from 9 years up to 12 years old.

Inclusion Criteria: - Parents provide free and informed consent and children assent to participate in the research, complete measures, and participate in either Coping Power or individualized treatment. - Parents report symptoms consistent with clinical diagnoses of Oppositional Defiant Disorder or Conduct Disorder on the Diagnostic Interview Schedule for Children - DSM IV or parents and/or teacher report at or above a T-score of 60 (93rd percentile; borderline clinically severe range) on the Externalizing Behavior composite scale on the Behavior Assessment for Children - 2nd edition. - Parents or teachers report clinically severe impairment in social, family, peer or overall functioning demonstrated by scores in the clinical range on the parent or teacher completed Impairment Rating Scale. - The child's cognitive functioning is at or above a standard score of 80 (Borderline Range) on the verbal and/or nonverbal scales on the Kaufman Brief Intelligence Task - 2. Exclusion Criteria: - Evidence of Autism Spectrum Disorder or Asperger's Disorder as reported by parent, teacher or physician referral (if available).

Additional Information

Official title Addressing Behaviour and Treatment Effectiveness Project (A.B.A.T.E. Project)
Principal investigator Brendan F Andrade, Ph.D.
Description This project compares the short- and long-term effectiveness of a clinic-adapted manualized group treatment (i.e., Coping Power; CP) to individualized child and family treatment for children aged 9 - 12 with disruptive behaviour. Children and their parents who meet criteria and agree to participate in the project are randomly assigned to either the CP condition or the Individualized treatment condition. In the CP condition, children and caregivers are asked to participate in two separate but complimentary 15-session groups. Child groups target development of children's emotional and cognitive problem solving skills and caregiver groups facilitate cognitive and behavioural parenting skills. In the Individualized treatment condition children and caregivers are asked to participate in 15 one-hour individual and family treatment sessions tailored by the clinician to address the children and parent's presenting concerns. Measurement of behaviour and emotional functioning is done pre- post- and at 6-months following treatment.
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Centre for Addiction and Mental Health.